Human CD19 Mouse mAb APC conjugated

Catalog No: #C92949APC

Package Size: #C92949APC 100ul



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com


Description

Product Name	Human CD19 Mouse mAb APC conjugated
Host Species	Mouse
Clonality	Monoclonal
Clone No.	MR4518
Isotype	IgG1
Purification	Affinity Purified
Applications	FC
Species Reactivity	Human
Immunogen Type	peptide
Immunogen Description	A synthesized peptide derived from Human CD19
Target Name	CD19
Other Names	CD19_HUMAN; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19;
	T-cell surface antigen Leu-12; CD_antigen: CD19; B-lymphocyte surface antigen B4; Leu 12; Leu12;
Calculated MW	61kD
Formulation	Liquid in PBS with 0.05% Proclin300, 1% BSA
Storage	Store at 4°C for 12 months.

Application Details

FC-5∃OL per test for million cells or whole blood in 100 ∃OL volume.

Images



Flow Cytometry analysis of Human peripheral blood lymphocytes stained with APC CD19 antibody (filled gray histogram). Unstained lymphocytes (empty black histogram) are used as control.

Background

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large

C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]

Note: This product is for in vitro research use only and is not intended for use in humans or animals.